Precision Medicine funding opportunities include coordinating center and biobank

The National Institutes of Health has released the first set of funding opportunities set to build the Precision Medicine Initiative (PMI). 

These projects will build a “solid infrastructure for the PMI Cohort Program” including a coordinating center, biobank, network of healthcare provider organizations and participant mobile technologies, according to NIH Director Francis Collins, MD. 

Of the $215 million requested in President Obama's fiscal year 2016 budget for PMI, NIH would receive $200 million for the launch of the national cohort of more than a million volunteers the administration hopes will share their genetic information and other health data to be used to expand current genomics research. The coordinating center will provide a set of analysis tools and perform data integration across a wide variety of data types, including participant self-reporting, sensor and app-generated data, clinical data from EHR systems and individuals enrolled as direct volunteers. The biobank will establish methods and technologies for sample collection, processing, handling, management, storage and providing all support services needed for biospecimen collection.

A Participant Technologies Center will develop, test, maintain and upgrade PMI Cohort Program mobile apps and associated server systems that will provide enrollment, consent, data collection and communication and feedback functions in a secure environment.

“Pending Congressional appropriations, NIH will begin building the infrastructure for this historic, first-of-its-kind study so enrollment in the cohort can begin in 2016,” said Collins. “It will take volunteers from all walks of life to build a resource that will help scientists answer a wide range of important health questions to improve treatments for a broad range of diseases and to prevent them in the first place."

NIH also announced a funding opportunity for a pilot program to inform the creation of the direct volunteer enrollment component of the cohort. The purpose of this effort is to invite applications for a prototype set of technologies and experiments that support the establishment of “innovative methods and technologies for data collection and management, and participant engagement.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.